Efficacy of a Whole Cell Algae Fermentate on Gut Health and Overall Immune Function in Healthy Adults With Mild Gastrointestinal Issues
A Randomized, Double-blind, Placebo-controlled, Crossover Study to Assess the Efficacy of a Patented Whole Cell Algae Fermentate on Gut Health in Healthy Adults With Mild Gastrointestinal Issues
研究概览
详细说明
This study is a randomized, placebo-controlled, crossover trial with a screening visit and two test periods separated by a three-week washout period.
At Visit 1, after subjects have provided informed consent, medical history will be reviewed and clinic visit procedures will be performed, including assessments of prior/current medication/supplement use, and evaluations of inclusion/exclusion criteria.Subjects will be dispensed a diet record, gastrointestinal questionnaire, bowel habits diary, upper respiratory symptom questionnaire, and a stool collection kit to complete prior to Visit 2 (week 0).
At Visit 2 (week 0), eligible subjects will return to the clinic. The stool samples will be collected, and the diet record, gastrointestinal questionnaire, and bowel habits diary will be collected. Subjects will also be administered a stress questionnaire and quality of life questionnaire. Eligible subjects will then be randomized to one of two test groups (placebo or active). Subjects will track study product intake using a daily study product log and track daily cold symptoms. Subjects will also be given a gastrointestinal questionnaire, bowel habits diary, upper respiratory symptom questionnaire, and a stool collection kit to complete prior to Visit 3 (week 4).
At Visit 3 (week 4), the stool samples will be collected, and the diet record, gastrointestinal questionnaire, and bowel habits diary will be collected. Subjects will also be administered a stress and quality of life questionnaire. Unused study product will be collected and compliance assessed via unused study product.Subjects will also be given a gastrointestinal questionnaire, bowel habits diary, and a stool collection kit to complete prior to Visit 4 (week 7)
Subjects will then enter the 3-week washout period, during which time no surveys/questionnaires will be kept and will then crossover to the other study product in their test sequence and repeat the Test Period I procedures (at Visit 2 and 3) during Test Period II (Visits 4 [week 7] and 5 [week 11]).
研究类型
注册 (实际的)
阶段
- 不适用
联系人和位置
学习地点
-
-
Illinois
-
Addison、Illinois、美国、60101
- Biofortis Innovation Services
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Subject is a male or female, 21-60 years of age
- Subject has a BMI of 18.5-34.9 kg/m2
- Subject reports having mild GI issues
- Subject is willing and able to comply with the collection and storage requirements of the stool samples
- Subject has internet access via computer, phone or other device and is able to maintain internet access throughout the trial in order to complete online daily questionnaires
- Subject is a non-user of all tobacco, smoking products and nicotine products
- Subject is willing to maintain physical activity patterns, body weight, supplements/medications, sleep patterns, and habitual diet throughout the trial.
- Subject has no health conditions that would prevent him from fulfilling the study requirements 9 Subject understands the study procedures and signs forms providing informed consent to participate in the study
Exclusion Criteria:
- Subject has an abnormal laboratory test result(s) of clinical importance at Visit 1
- Subject has a clinically important GI condition that would potentially interfere with the evaluation of the study product
- Subject has a history or presence of uncontrolled and/or clinically important pulmonary (including uncontrolled asthma), cardiac (including, but not limited to, atherosclerotic disease, history of myocardial infarction, peripheral arterial disease, stroke), hepatic, renal, endocrine (including type 1 and type 2 diabetes mellitus), hematologic, immunologic, neurologic (such as Alzheimer's or Parkinson's disease), psychiatric (including unstable depression and/or unstable anxiety disorders) or biliary disorders
- Subject has a known allergy, intolerance, or sensitivity to any of the ingredients in the study products
- Subject has extreme dietary habits (e.g., Atkins diet, very high protein, very high fiber)
- Subject has uncontrolled hypertension
- Subject has a recent (within 6 weeks of Visit 1) diarrhea (defined as ≥3 loose or liquid stools/d)
- Subject has participated in colonoscopy or colonoscopy preparation within 3 months prior to Visit 1
- Subject has a history or presence of cancer in the prior two years, except for non-melanoma skin cancer
- Subject has a history of bariatric surgery for weight reducing purposes
- Subject has had a weight gain or loss of ≥5% body weight within 6 months of Visit 1
- Subject has experienced any major trauma or any other surgical event within three months of Visit 1
- Subject has any signs or symptoms of an active infection (including diarrhea) of clinical relevance within 5 days of Visit 1
- Subject has used antibiotics within 3 months of Visit 1 or throughout study period
- Subject has used medications (over-the-counter or prescription) or dietary supplements known to influence GI function
- Subject has used medications or supplements known to influence immune responses
- Subject is a regular user (>3 times/week) of prescribed anti-inflammatory medications within 30 d of Visit 1
- Subject is a regular user (i.e., >1 time per month) of allergy medications
- Subject has used weight-loss medications
- Subject is a female who is pregnant, planning to be pregnant during the study period, lactating, or is of childbearing potential and is unwilling to commit to the use of a medically approved form of contraception throughout the study period
- Subject has a recent history of (within 12 months of screening; Visit 1; week -1) or strong potential for alcohol or substance abuse
- Individual has a condition the Clinical Investigator believes would interfere with his ability to provide informed consent, comply with the study protocol, which might confound the interpretation of the study results, or put the subject at undue risk
学习计划
研究是如何设计的?
设计细节
- 主要用途:卫生服务研究
- 分配:随机化
- 介入模型:交叉作业
- 屏蔽:四人间
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
安慰剂比较:Placebo
Microcystalline Cellulose
|
微晶纤维素
|
|
实验性的:Treatment
Whole Cell Algae Fermentate
|
Contains at minimum 50% Beta Glucan
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Gastrointestinal symptom
大体时间:After 4 weeks of each test period
|
Gastrointestinal Tolerability Questionnaire
|
After 4 weeks of each test period
|
|
Gastrointestinal ease and consistency
大体时间:After 4 weeks of each test period
|
Bristol Stool Scale
|
After 4 weeks of each test period
|
|
Cold/Flu Symptoms
大体时间:After 4 weeks of each test period
|
Wisconsin Upper Respiratory Symptom Survey
|
After 4 weeks of each test period
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Fecal Microbiome
大体时间:After 4 weeks of each test period
|
Omnigene-GUT DNA Genotek
|
After 4 weeks of each test period
|
|
Fecal biomarker 1
大体时间:After 4 weeks of each test period
|
Short Chain Fatty Acid
|
After 4 weeks of each test period
|
|
Fecal biomarker 2
大体时间:After 4 weeks of each test period
|
Leaky Gut biomarker
|
After 4 weeks of each test period
|
|
Stress Questionnaire
大体时间:After 4 weeks of each test period
|
Perceived Stress Questionnaire
|
After 4 weeks of each test period
|
|
Quality of Life Questionnaire
大体时间:After 4 weeks of each test period
|
World Health Organization-Quality of Life Questionnaire
|
After 4 weeks of each test period
|
合作者和调查者
调查人员
- 首席研究员:Andrea Lawless, MD、Biofortis Innovation Services
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- BIO-1901
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.